Pharmidex will be attending “The 17th Annual BIO CEO & Investor Conference”
February 9, 2015

The BIO CConference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.

Pharmidex will be attending “The 17th Annual BIO CEO & Investor Conference”

Pharmidex will be attending

The BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.


Those attending the conference will have the opportunity to explore a broad variety of industry related investment opportunities. Additionally delegates would have a chance to network with institutional investors, industry analysts & senior biotechnology executives. 


Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. BIO One-on-One Partnering provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.


The event will be taking place on the 9-10 February 2015, New York City, NY, USA.

May 8, 2025
At Pharmidex, we are proud to contribute to scientific innovation through robust and reliable bioanalytical support from early discovery to regulated studies. For over eight years, we've partnered with Shimadzu, using their LCMS-8060 and LC-2050 systems to deliver high-quality, data-driven results tailored to diverse client needs. Their instruments have played a key role in advancing our bioanalytical capabilities and supporting the success of our collaborative projects. Our Head of Operations, Ash Alavijeh , recently shared insights from our long-standing collaboration as part of Shimadzu’s 150th anniversary testimonial series. We are honored to be part of their journey and look forward to continuing this partnership built on shared values of precision, reliability, and innovation. 👉 Read more stories from the Shimadzu global community here .
May 7, 2025
At Pharmidex, we stand in solidarity with individuals and families affected by Huntington’s Disease a rare, inherited neurodegenerative condition that impacts the mind, body, and spirit. Throughout May, we reaffirm our commitment to advancing neuroscience research and supporting drug discovery efforts aimed at neurodegenerative diseases. Our team is proud to collaborate with partners working toward meaningful therapies that can improve quality of life and bring hope to the HD community. Let’s raise awareness. Let’s drive innovation. Let’s stand together.
C3 Summit London
May 5, 2025
We’re pleased to share that Mo Yaqoob from our Business Development team will be attending the C3 Summit on 8 May 2025 at 8 Northumberland Ave, London. 🔗 https://www.thec3summit.com/london-2025/  Mo is looking forward to meeting fellow attendees, exploring new partnerships, and discussing how we can work together to accelerate the development of innovative drug candidates. If you're attending, don’t hesitate to connect let’s spark the next great collaboration!
More Posts